Challenges of defining renal response in ANCA-associated vasculitis: call to action?
暂无分享,去创建一个
[1] P. Merkel,et al. An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. , 2022, Seminars in arthritis and rheumatism.
[2] J. Aniort,et al. Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges , 2022, Journal of the American Society of Nephrology : JASN.
[3] M. Säemann,et al. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors , 2021, Annals of the Rheumatic Diseases.
[4] M. Kretzler,et al. The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis , 2021, Journal of the American Society of Nephrology : JASN.
[5] R. Hunter,et al. Utility of interval kidney biopsy in ANCA-associated vasculitis , 2021, Rheumatology.
[6] U. Specks,et al. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] G. Ghiggeri,et al. Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[8] P. Korsten,et al. Proteinuria Indicates Decreased Normal Glomeruli in ANCA-Associated Glomerulonephritis Independent of Systemic Disease Activity , 2021, Journal of clinical medicine.
[9] A. Meara,et al. ANCA-Associated Vasculitis: An Update , 2021, Journal of clinical medicine.
[10] W. Cushman,et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. , 2021, Kidney international.
[11] A. Woywodt,et al. Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects. , 2021, Kidney360.
[12] C. Pusey,et al. Glucocorticoid-free treatment of severe ANCA-associated vasculitis , 2020, Nephrology Dialysis Transplantation.
[13] V. Tesar,et al. Mass spectrometry-based proteomic exploration of the small urinary extracellular vesicles in ANCA-associated vasculitis in comparison with total urine. , 2020, Journal of proteomics.
[14] A. Levin,et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. , 2020, Kidney international.
[15] A. Vaglio,et al. Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome , 2020, Clinical kidney journal.
[16] Victor G. Puelles,et al. Deep learning-based molecular morphometrics for kidney biopsies , 2020, bioRxiv.
[17] O. Dekkers,et al. Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. , 2020, Clinical journal of the American Society of Nephrology : CJASN.
[18] D. Jayne,et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations , 2020, RMD Open.
[19] T. Rabelink,et al. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] P. Merkel,et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis , 2020, Annals of the Rheumatic Diseases.
[21] P. Merkel,et al. Clinical associations of renal involvement in ANCA-associated Vasculitis. , 2020, Autoimmunity reviews.
[22] A. Levin,et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. , 2020, The New England journal of medicine.
[23] J. Stone,et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. , 2019, Rheumatology.
[24] Sarah A. Teichmann,et al. Spatiotemporal immune zonation of the human kidney , 2019, Science.
[25] C. Reutelingsperger,et al. Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. , 2019, Kidney international.
[26] P. Bekker,et al. Effect of Disease Activity at Three and Six Months After Diagnosis on Long‐Term Outcomes in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2019, Arthritis & rheumatology.
[27] T. Bijma,et al. Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] Hyon K. Choi,et al. All‐Cause and Cause‐Specific Mortality in Patients With Granulomatosis With Polyangiitis: A Population‐Based Study , 2018, Arthritis care & research.
[29] G. Fogazzi,et al. Microscopic examination of urine sediment: Phase contrast versus bright field. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[30] J. Levy,et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis , 2018, Rheumatology.
[31] P. Höglund,et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome , 2018, Rheumatology.
[32] V. Tesar,et al. Avacopan in the treatment of ANCA-associated vasculitis , 2018, Expert opinion on investigational drugs.
[33] S. Ohlsson,et al. Monocyte Chemoattractant Protein-1 in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Biomarker Potential and Association with Polymorphisms in the MCP-1 and the CC Chemokine Receptor-2 Gene , 2018, Mediators of inflammation.
[34] P. Merkel,et al. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[35] Min Chen,et al. Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis? , 2017, BMC Nephrology.
[36] C. Pusey,et al. The role of monocytes in ANCA-associated vasculitides. , 2016, Autoimmunity reviews.
[37] D. Schroeder,et al. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 , 2016, Arthritis & rheumatology.
[38] Rohit Sharma. Revised International Chapel Hill Consensus Conference nomenclature of vasculitides , 2016, Radiopaedia.org.
[39] D. Jayne,et al. End‐stage renal disease in ANCA‐associated vasculitis , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] T. Cavero,et al. Rituximab for treatment of severe renal disease in ANCA associated vasculitis , 2016, Journal of Nephrology.
[41] A. Salama,et al. Prolonged Duration of Renal Recovery Following ANCA-Associated Glomerulonephritis , 2016, American Journal of Nephrology.
[42] C. Feighery,et al. Urinary Soluble CD163 in Active Renal Vasculitis. , 2016, Journal of the American Society of Nephrology : JASN.
[43] Paul A. Lyons,et al. T cell exhaustion, costimulation and clinical outcome in autoimmunity and infection , 2015, Nature.
[44] P. Merkel,et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. , 2015, Journal of the American Society of Nephrology : JASN.
[45] P. van Paassen,et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. , 2015, Journal of the American Society of Nephrology : JASN.
[46] D. Geetha,et al. Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. , 2014, Seminars in arthritis and rheumatism.
[47] V. Lánská,et al. Repeat protocol renal biopsy in ANCA-associated renal vasculitis. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] C. Stegeman,et al. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[49] P. van Paassen,et al. Estimating renal survival using the ANCA-associated GN classification. , 2013, Journal of the American Society of Nephrology : JASN.
[50] M. Tonelli,et al. Proteinuria and rate of change in kidney function in a community-based population. , 2013, Journal of the American Society of Nephrology : JASN.
[51] L. Mouthon,et al. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? , 2013, Annals of the rheumatic diseases.
[52] R. Sinico,et al. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. , 2013, Autoimmunity reviews.
[53] P. Seo,et al. Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy , 2012, The Journal of Rheumatology.
[54] V. Tesar,et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. , 2011, Rheumatology.
[55] Irmgard Neumann,et al. Histopathologic classification of ANCA-associated glomerulonephritis. , 2010, Journal of the American Society of Nephrology : JASN.
[56] J. Myles,et al. Persistent Hematuria After Induction of Remission in Wegener Granulomatosis: A Therapeutic Dilemma , 2009, Medicine.
[57] P. Nightingale,et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis , 2009, Annals of the rheumatic diseases.
[58] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[59] D. Abramowicz,et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.
[60] Jianwen Cai,et al. Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis , 2005, Annals of Internal Medicine.
[61] C. Feighery,et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.
[62] C. Kallenberg,et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[63] M. Haas,et al. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. , 2004, Kidney international.
[64] C. Pusey,et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[65] B. Rozman,et al. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[66] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[67] H. V. van Houwelingen,et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. , 2002, Kidney international.
[68] C. Kallenberg,et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. , 1998, Journal of the American Society of Nephrology : JASN.
[69] E. Neilson,et al. Mechanisms of tubulointerstitial fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.
[70] J. Sayer,et al. Identification and significance of dysmorphic versus isomorphic hematuria. , 1990, The Journal of urology.
[71] D. Jayne,et al. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[72] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[73] P. Merkel,et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. , 2012, Rheumatology.
[74] P. Seo. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis , 2010 .
[75] A. Soleiman,et al. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[76] M. Boomsma. Anca associated vasculitis , 2001 .